Belgian Economic Mission to India highlights collaborations in lifesciences sector
Bringing together leaders, researchers, and stakeholders in the life sciences sector, this event aims to showcase how Belgium and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
oncology
VeGen Labs secures BIRAC funding to advance KRAS Inhibitor
The BIRAC funding will enable comprehensive toxicology assessments, a critical step in preparing for IND submission with…
Zydus Lifesciences signs agreement with Synthon BV for 505(B)(2) oncology product
Zydus to handle NDA submission and commercialisation in the US; Synthon to lead development and manufacturing
Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT…
ISB 2001 demonstrated an ORR of 83 per cent in heavily pretreated patients treated at active doses (0.05 mg/kg and higher)
Sun Pharma and Philogen sign global licensing agreement for Fibromun
Agreement focuses on global commercialisation of anti-cancer immunotherapy
Lupin launches Doxorubicin Hydrochloride Liposome Injection in the United States
Lupin expands oncology portfolio with the launch of a generic version of Doxil in the U.S.
Our aim is to tailor our oncology portfolio to address the most pressing needs in India
Pratima Reddy, Country Speaker for Merck India & MD, Merck Specialties elaborates on the company’s partnerships with national…
AstraZeneca sets $80 billion revenue target by 2030
Company aims to launch 20 new medicines by 2030, and reduce carbon emissions
Alembic Pharmaceuticals receives an EIR for its oncology formulation facility
According to the company’s statement, all EIRs are in place for their USFDA facilities
Zydus launches IBYRA, the generic version of Olaparib
The drug will target specific genetic mutations prevalent in certain types of cancers